According to a report by TechSci Research, the global biosimilar contract manufacturing market is expected to grow at an impressive rate from 2024 to 2028. This growth is driven by the increasing prevalence of diabetes, cancer, neurological disorders, and the availability of lower-cost biosimilars compared to branded products. Additionally, the focus on contract development in countries like China and India and the increasing prevalence of autoimmune diseases are expected to create lucrative opportunities for market growth.
However, the high cost of biosimilar drugs and subsequent therapies for chronic diseases may slow down market growth. High risks and complications associated with biosimilar drugs, a lack of skilled professionals, poor reimbursement scenarios, and limited insurance coverage for cancer treatment in emerging countries may also hinder market growth.
The global biosimilar contract manufacturing market can be segmented by product, technology, application, and region. By product, the market is divided into recombinant non-glycosylated proteins and recombinant glycosylated proteins. The recombinant non-glycosylated protein segment dominated the market in 2021 due to increasing demand for monoclonal antibodies and rising incidence of diabetes.
By application, the market is segmented into oncology, blood disorders, growth hormone deficiency, chronic and autoimmune disorders, rheumatoid arthritis, and others. The oncology segment is expected to dominate due to the increasing prevalence of cancer and the high cost of cancer drugs and treatment.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on “Biosimilar Contract Manufacturing Market” – https://www.techsciresearch.com/report/biosimilar-contract-manufacturing-market/14416.html
Major companies operating in global biosimilar contract manufacturing market are:
- Catalent, Inc.
- Boehringer Ingelheim GmbH
- Alcami Corporation, Inc.
- Almac Group
- Lonza Group AG
- Biocon Limited
- Avid Bioservice, Inc
- Rentschler Biopharma SE
- Fujifilm Kyowa Kirin Biologics Co., Ltd.
- WuXi Biologics, Inc.
On August 25, 2021, Cipla Limited, a leading global pharmaceutical company, and Kemwell Biopharma Private Limited, a leading biopharmaceutical Biopharmaceuticals Contract Manufacturing (CDMO) announced the execution of a joint venture agreement to develop, manufacture and commercialize biosimilars for global markets.
On August 28, 2020, iBio and Planet Biotechnology entered into an exclusive worldwide license agreement for the development of a COVID-19 therapeutics.
on April 13, 2021, Lonza, a leading global Biopharmaceuticals Contract Manufacturing (CDMO)/ CMO, and Junshi Biosciences, an innovative Chinese pharmaceutical company collaborated to accelerate the development and manufacturing of biologics using Lonza’s GS Xceed® Gene Expression System.
Customers can also request for 10% free customization on this report.
“The North American region is expected to dominate in the global biosimilar contract manufacturing market due to the increasingly developed biosimilar contract organizations in the developing countries. Furthermore, increasing developed healthcare infrastructure and increasing product introductions are further contributing to the demand for biosimilar contract manufacturing. Similarly, growing approvals of biosimilar drugs in recent years and growing demand for less expensive therapeutic products, and the high prevalence of chronic diseases are expected to drive market growth over the years. Additionally, the increasing the incidence of non-communicable diseases such as diabetes and autoimmune disorders is fueling the demand for cost-effective treatments and will drive market growth over the years. Besides, increasing demand for less expensive therapeutic products and increasing prevalence of chronic diseases like cancers in the region are further expected to create lucrative opportunities for the market growth” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Biosimilar Contract Manufacturing Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F, Segmented By Product (Recombinant Non-glycosylated Proteins v/s Recombinant Glycosylated Proteins), By Technology (Mammalian v/s non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others), By Region and Competition”, has evaluated the future growth potential of global biosimilar contract manufacturing market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global biosimilar contract manufacturing market.
Report Scope:
In this report, global biosimilar contract manufacturing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Biosimilar Contract Manufacturing Market, By Product:
o Recombinant Non-glycosylated Proteins
o Recombinant Glycosylated Proteins
Biosimilar Contract Manufacturing Market, By Technology:
o Mammalian
o Non-Mammalian
Biosimilar Contract Manufacturing Market, By Application:
o Oncology
o Blood Disorders
o Growth Hormonal Deficiency
o Chronic & Autoimmune Disorders
o Rheumatoid Arthritis
o Others
Biosimilar Contract Manufacturing Market, By Region:
o North America
o Asia Pacific
o South America
o Middle East & Africa
Download Free Sample Report – https://www.techsciresearch.com/sample-report.aspx?cid=14416
About TechSci Research:
TechSci Research is a research-based management consulting firm providing market research and advisory solutions to its customers worldwide, spanning a range of industries. TechSci Research’s core values are value, integrity and insight. Led by a team of dynamic industry experts, TechSci Research provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, TechSci’s client leads rather than follow market trends. Not bound by legacy, TechSci’s cutting-edge research model leverages its decades of research knowledge and increased use of technology as engines of innovation to deliver unique research value. Provided as an alternative to traditional market research, TechSci Research reports do not just deliver data and knowledge rather highlights the insights in a more usable and interactive format for its clients.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]Web: https://www.techsciresearch.com